系统综述:克罗恩病中升阶梯维持抗TNF治疗的疗效
该系统综述检索EMBASE、MEDLINE、Web of Science和CENTRAL数据库至2021年4月25日,纳入68篇评估成人克罗恩病患者升阶梯维持治疗(英夫利昔单抗或阿达木单抗)的全文文章。结果显示,因标准抗TNF治疗失去反应而经验性升阶梯后,临床反应率(33%-100%)和缓解率(15%-83%)较高但研究间差异大;剂量加倍与缩短间隔疗效相似;升阶梯患者血清药物水平 tended 更高;比较TDM与经验性 intensification 的RCT未达主要终点;贝叶斯dashboard给药和早期升阶梯至生物标志物正常化与改善长期结局相关。
要点
- 经验性升阶梯维持抗TNF治疗可使多数继发性失应答的克罗恩病患者重获临床反应。
- 剂量加倍与缩短治疗间隔两种强化策略疗效相似。
- 主动优化维持剂量可能延长部分患者至失应答的时间。
核心结论
- 经验性升阶梯维持抗TNF治疗可使多数标准维持剂量继发性失应答的克罗恩病患者重获临床反应。
- 主动优化维持剂量可能延长部分患者至失应答的时间。
研究设计与样本
- 系统综述检索EMBASE、MEDLINE、Web of Science和CENTRAL数据库至2021年4月25日的英文文献。
- 共识别4733条记录,68篇文章符合纳入标准,评估成人克罗恩病患者升阶梯维持治疗(英夫利昔单抗或阿达木单抗)。
主要发现
- 因标准抗TNF治疗失去反应而经验性升阶梯后,临床反应率为33%-100%,缓解率为15%-83%,但研究间差异大。
- 剂量强化策略(剂量加倍与缩短治疗间隔)疗效相似。
- 升阶梯患者相比标准剂量患者血清药物水平 tended 更高。
- 多项观察性研究发现升阶梯后存在暴露-反应关系。
- 比较治疗药物监测(TDM)与经验性治疗强化的随机对照试验未达到主要终点。
临床怎么用
- 对标准维持剂量抗TNF治疗继发性失应答的克罗恩病患者,可考虑经验性升阶梯治疗以重获临床反应。
- 剂量加倍或缩短治疗间隔均可作为升阶梯策略,两者疗效相似。
- 主动优化维持剂量可能延长部分患者至失应答的时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Loss of response to anti-TNF agents is a common clinical problem. Dose escalation may be effective for reestablishing clinical response in Crohn's disease (CD). AIMS: To perform a systematic review assessing the efficacy of escalated maintenance anti-TNF therapy in CD. METHODS: EMBASE, MEDLINE, Web of Science, and CENTRAL databases were searched for English language publications through to April 25, 2021. Full-text articles evaluating escalated maintenance treatment (infliximab or adalimumab) in adult CD patients were included. RESULTS: A total of 4733 records were identified, and 68 articles met eligibility criteria. Rates of clinical response (33%-100%) and remission (15%-83%) after empiric dose escalation for loss of response to standard anti-TNF therapy were high but varied across studies. Dose intensification strategies (doubling the dose versus shortening the therapeutic interval) were similarly efficacious. Dose-escalated patients tended to have higher serum drug levels compared to those on standard dosing. An exposure-response relationship following dose escalation was found in a number of observational studies. Randomised controlled trials comparing therapeutic drug monitoring (TDM) to empiric treatment intensification have failed to reach their primary end-points. Strategies including Bayesian dashboard-dosing and early treatment escalation targeting biomarker normalisation were found to be associated with improved long-term outcomes. CONCLUSIONS: Empiric escalation of maintenance anti-TNF therapy can recapture clinical response in a majority of patients with secondary loss of response to standard maintenance doses. Proactive optimisation of maintenance dosing might prolong time to loss of response in some patients.
引用
- Mattoo VY, Basnayake C, Connell WR, et al. Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease. Aliment Pharmacol Ther. 2021. PMID: 34153124. doi:10.1111/apt.16479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。